Kapitalo Investimentos Ltda Purchases New Position in Johnson & Johnson (NYSE:JNJ)

Kapitalo Investimentos Ltda bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,429 shares of the company's stock, valued at approximately $351,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after buying an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after acquiring an additional 1,561,036 shares during the period. Northern Trust Corp increased its stake in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter worth $4,390,037,000. Finally, Wellington Management Group LLP increased its position in Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after buying an additional 431,205 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on JNJ shares. Raymond James lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Wells Fargo & Company reduced their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Finally, Bank of America cut their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $171.82.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Up 1.1 %

Shares of JNJ stock traded up $1.63 during mid-day trading on Friday, hitting $156.09. 5,973,317 shares of the stock traded hands, compared to its average volume of 7,879,758. The stock's fifty day moving average is $159.05 and its two-hundred day moving average is $154.73. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock has a market cap of $375.56 billion, a P/E ratio of 23.47, a P/E/G ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.33%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.